This is a routine insider onboarding filing with no trading or financial implications. Monitor future Form 4 filings from Tadvalkar for any insider transactions that may signal conviction or concern.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $34.00entry
- T+1 · 7mo ago −25.47%α −25.13% · $25.34
- T+5 · 6mo ago −26.12%α −28.46% · $25.12
- T+20 · 6mo ago −20.21%α −25.47% · $27.13
- T+60 · 4mo ago +39.00%α +35.93% · $47.26
Price Chart
How similar events traded
Executive Summary
Laura Tadvalkar filed a Form 3 initial statement of beneficial ownership with Hemab Therapeutics Holdings, Inc. (COAG), indicating she has become a reporting insider (officer, director, or >10% holder). The filing is administrative and includes a power of attorney authorizing others to file future SEC reports on her behalf. No financial data, share amounts, or transaction details are disclosed.
Key Facts
- Form 3 filed by Laura Tadvalkar as a new reporting insider of Hemab Therapeutics Holdings, Inc.
- Filing includes a power of attorney authorizing Mads Nikolaj Behrndt, Benny Sørensen, and Klaus Krainer Jønsson to file future SEC reports on her behalf.
- No beneficial ownership amounts or securities transactions are disclosed in the filing.
- The filing is dated April 30, 2026, with a period of report of April 30, 2026.
Financial Impact
No financial impact, the filing is a routine initial ownership disclosure with no monetary figures.
Risk Factors
- No material risks identified from this filing alone.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-198198 |
| Document: 0001193125-26-198198-index-headers.html | 0001193125-26-198198 |
| Document: 0001193125-26-198198-index.html | 0001193125-26-198198 |
| Document: 0001193125-26-198198.txt | 0001193125-26-198198 |
Track record
19 reports on COAG
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $38.77 Now $39.06 +0.75% settles Nov 17
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
- Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
- Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
- Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
- May 21, 202625w ago Press Release Neutral 5/10 Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
- May 4, 202628w ago 8-K Neutral 4/10 Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers